Plain-English translation of NCT03093116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing an experimental oral medication called repotrectinib in people with advanced solid tumors that have specific genetic mutations (ROS1, ALK, or NTRK). The study is divided into two phases: Phase 1 focuses on finding the right dose and checking safety in a small group of patients, while Phase 2 tests how well the medication works in larger groups of people with different treatment histories. Researchers hope this medication will help patients whose tumors have these particular genetic changes.
Some solid tumors have rare genetic mutations that make them grow in specific ways. Current treatments don't work well for all patients with these mutations, especially those who have already tried other medications. This trial aims to see if the new treatment can help people whose cancer has progressed despite other therapies.
You likely qualify if…
You likely don't qualify if…
In Phase 1, you would visit the clinic regularly to take the medication by mouth and have blood tests and imaging scans to monitor how your body tolerates it and how the tumor responds. In Phase 2, you would join one of six study groups based on your specific diagnosis and treatment history, continue taking the medication at home, and return for periodic check-ups and tests. The study continues until your cancer progresses, you experience unacceptable side effects, or the research is complete.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States